IL17A and melanoma: Analysis of IFN-γ, IL-17 and IL-10 supernatant levels from 5-day melanoma patient derived PBMC cell cultures (Figure 6 and Supplementary Figure 2), revealed relatively modest differences in IFN-γ supernatant increases between treatments, with significant increases in levels observed only with both anti-sCTLA-4 mAbs JMW-3B3 and 73-B1 anti-sCTLA-4 clones stimulated significant increases in IFN-γ compared with ipilimumab at low levels of anti-CD3 mAb (0.02 μg/mL) stimulation.